Prices are closing data as of 2026-11-09, not real-time quotes. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for Guardant Health, Inc.?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Key Multi-Year Facts
- Revenue moved from $25.2M in FY2016 to $982.0M in FY2025 (9-year CAGR +50.2%).
- Net income was negative in FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024, FY2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (USD B) | 0.37 | 0.45 | 0.56 | 0.74 | 0.98 |
| YoY | 30.3% | 20.3% | 25.5% | 31.0% | 32.9% |
| Net Income (USD B) | -0.38 | -0.65 | -0.48 | -0.44 | -0.42 |
| Operating Cash Flow (USD B) | -0.21 | -0.31 | -0.32 | -0.24 | -0.18 |
| ROE | -39.6% | -185.7% | -438.1% | — | — |
| Gross Margin | — | — | 59.7% | 60.8% | 64.5% |
| Net Margin | -103.0% | -145.6% | -85.0% | -59.1% | -42.4% |
| Debt-to-Assets | 70.7% | 96.3% | 91.1% | 109.4% | 104.9% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD B) | 0.03 | 0.05 | 0.09 | 0.21 | 0.29 | 0.37 | 0.45 | 0.56 | 0.74 | 0.98 |
| YoY | — | 97.4% | 81.9% | 136.5% | 33.8% | 30.3% | 20.3% | 25.5% | 31.0% | 32.9% |
| Net Income (USD B) | -0.05 | -0.08 | -0.09 | -0.08 | -0.25 | -0.38 | -0.65 | -0.48 | -0.44 | -0.42 |
| Operating Cash Flow (USD B) | -0.04 | -0.07 | -0.07 | -0.05 | -0.10 | -0.21 | -0.31 | -0.32 | -0.24 | -0.18 |
| ROE | -57.9% | -42.9% | -21.5% | -11.8% | -24.2% | -39.6% | -185.7% | -438.1% | — | — |
| Gross Margin | — | — | — | — | — | — | — | 59.7% | 60.8% | 64.5% |
| Net Margin | -182.7% | -167.0% | -93.8% | -35.3% | -88.5% | -103.0% | -145.6% | -85.0% | -59.1% | -42.4% |
| Debt-to-Assets | — | 10.0% | 10.6% | 11.9% | 40.3% | 70.7% | 96.3% | 91.1% | 109.4% | 104.9% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: SEC XBRL filings, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-10
Rules-based screening using SEC XBRL financial data and 8-K/NT material event filings (no AI opinions).
Items Flagged for Review
- Alert
- Alert
-
Alert
Net LossesGoing Concern
FY2025 (2025-12-31) $-0.42B, FY2024 (2024-12-31) $-0.44B
FY2025 (ended 2025-12-31)
-
Alert
Shareholders' EquityGoing Concern
Shareholders' equity $-0.28B, Retained earnings $-3.35B
Quarterly (2026-09-30) · What is this?
-
Watch
High Cash & High DebtSolvency
cash 54.5% of assets, total debt 79.7% of assets
Quarterly (2026-09-30)
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
More U.S. data: 500 largest U.S. companies · U.S. high dividend stocks · Is the stock market open today?
Compiled mechanically from public filings and market quotes (data as of 2026-11-10). For informational purposes only, not investment advice.